Find examples of successful applications of products and services from Svar Life Science in the reference list below.


Chow T, Shamszad P, Vinnard C, et al | Clin Transl Sci | 2023

First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor.

Cîrciumaru A, Afonso MG, Wähämaa H, et al | Biomolecules | 2023

Anti-Citrullinated Protein Antibody Reactivity towards Neutrophil-Derived Antigens: Clonal Diversity and Inter-Individual Variation

David Kavanagh, Larry A. Greenbaum, Arvind Bagga, et al | Kidney International Reports | 2023

Design and rationale of the APPELHUS Phase 3 open-label study of Factor B inhibitor iptacopan for atypical hemolytic uremic syndrome

Dieckmann R, Pullerits R, Bylund J, et al |  J Immunol Res | 2023

Antieosinophil Antibodies Alone or in Combination with Antineutrophil Cytoplasmic Antibodies (ANCA) Detected in Different Autoimmune Conditions

García-González M, Gómez-Bernal F, Quevedo-Abeledo JC, et al | Front Immunol. | 2023

Full characterization of the three pathways of the complement system in patients with systemic lupus erythematosus

Gerber, GF, Pan, XZ, Lederman, HM et al |  J Clin Immunol | 2023

Novel Functional Assay to Characterize Mutations in Alternative Pathway of Complement.

Ikeda Z, Kamei T, Sasaki Y, et al | J Med Chem. | 2023

Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway.

Simmons KT, Chan J, Hussain S, et al | Clin Immunol. | 2023

Anti-Citrullinated Protein Antibody Reactivity towards Neutrophil-Derived Antigens: Clonal Diversity and Inter-Individual Variation

Aghababa H, Ting YT, Pilapitiya D, et al | Virulence | 2022

Complement evasion factor (CEF), a novel immune evasion factor of Streptococcus pyogenes.

Garlich J, Cinier M, Chevrel A, et al | Biomolecules | 2022

Discovery of APL-1030, a Novel, High-Affinity Nanofitin Inhibitor of C3-Mediated Complement Activation.

Jaskowski TD, Martins TB, et al | J Clin Lab Anal | 2022

Comparison of four enzyme immunoassays for the detection of immunoglobulin G antibody against glomerular basement membrane

Kojima T, Inoue D, Wajima T, et al | Ren Fail | 2022

Circulating immune-complexes and complement activation through the classical pathway in myeloperoxidase-ANCA-associated glomerulonephritis

Breville G, Zamberg I, Sadallah S, et al | Front Immunol | 2021

Complement Alternative Pathway Thrombotic Microangiopathy (CAP-TMA) Disease Oriented Group at the Mayo Clinic. Monitoring Ravulizumab effect on complement assays.

Willrich MAV, Ladwig PM, Martinez MA, et al | J Immunol Methods | 2021

Complement Alternative Pathway Thrombotic Microangiopathy (CAP-TMA) Disease Oriented Group at the Mayo Clinic. Monitoring Ravulizumab effect on complement assays.

Bartoszek D, Mazanowska O, Kościelska-Kasprzak K, et al | Arch Immunol Ther Exp | 2019

Complement Alternative Pathway Thrombotic Microangiopathy (CAP-TMA) Disease Oriented Group at the Mayo Clinic. Monitoring Ravulizumab effect on complement assays.

Fridkis-Hareli M, Storek M, Or E, et al | Mol Immunol | 2019

The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models

Bartoszek D, Mazanowska O, Kościelska-Kasprzak K, et al | Transplant Proc | 2018

Functional Activity of the Complement System in Deceased Donors in Relation to Kidney Allograft Outcome

Bjerre A, Bergseth G, Ludviksen JK, et al | Case Rep Nephrol. | 2018

Clinical and Complement Long-Term Follow-Up of a Pediatric Patient with C3 Mutation-Related Atypical Hemolytic Uremic Syndrome

Høiland II, Liang RA, Hindberg K, et al | Thromb Res | 2018

Associations between complement pathways activity, mannose-binding lectin, and odds of unprovoked venous thromboembolism

Lung T, Matozan K, Risch M, et al | Diagnosis (Berl) | 2018

Complement systems C4, C3 and CH50 not subject to a circadian rhythm

Willrich MAV, Andreguetto BD, Sridharan M, et al | J Immunol Methods | 2018

The impact of eculizumab on routine complement assays

Poppelaars F, Damman J, de Vrij EL, et al | Clin Exp Immunol | 2016

New insight into the effects of heparinoids on complement inhibition by C1-inhibitor

Volokhina EB, van de Kar NC, Bergseth G, et al | Clin Immunol | 2015

Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome

Cugno M, Gualtierotti R, et al | J Thromb Haemost | 2014

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome

Korir JC, Nyakoe NK, et al | PLoS One. | 2014

Complement activation by merozoite antigens of Plasmodium falciparum

Roos A, Wieslander J. | Methods Mol Biol | 2014

Evaluation of complement function by ELISA

Inoshita H, Ohsawa I, Kusaba G, et al | BMC Nephrol | 2010

Complement in patients receiving maintenance hemodialysis: functional screening and quantitative analysis

Orth D, Ehrlenbach S, Brockmeyer J, et al | Infect Immun | 2010

EspP, a serine protease of enterohemorrhagic Escherichia coli, impairs complement activation by cleaving complement factors C3/C3b and C5

Salvesen B, Mollnes TE. | Mol Immunol | 2009

Pathway-specific complement activity in pigs evaluated with a human functional complement assay

Ito-Ihara T, Muso E, Kobayashi S, et al | Clin Exp Rheumatol | 2008

A comparative study of the diagnostic accuracy of ELISA systems for the detection of anti-neutrophil cytoplasm antibodies available in Japan and Europe

Varga L, Széplaki G, Laki J, Kocsis A, et al | Clin Exp Immunol | 2008

Depressed activation of the lectin pathway of complement in hereditary angioedema

Csernok E, Holle J, Hellmich B, et al | Rheumatology (Oxford) | 2004

Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study

Villalta D, Tonutti E, Tampoia M, et al | Clin Chem Lab Med | 2004

Analytical and diagnostic accuracy of the EliA automated enzyme fluoroimmunoassay for antineutrophil cytoplasmic autoantibody detection

Segelmark M, Phillips BD, Hogan SL, et al | Clin Diagn Lab Immunol | 2003

Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis


Jung YE, Lee KW, Cho JH, et al | Sci Rep | 2023

Heating-mediated purification of active FGF21 and structure-based design of its variant with enhanced potency

Lallemand, C., Fernando-Miguel, et al | Medical Research Archives | 2023

Analysis of Bevacizumab Activity Following Treatment Patients with Ovarian Cancer or Glioblastoma

Guo K, Barrett BS, Morrison JH, et al | Proc Natl Acad Sci U S A | 2022

Interferon resistance of emerging SARS-CoV-2 variants

Guo K, Shen G, Kibbie J, et al | PLoS Pathog | 2022

Qualitative Differences Between the IFNα subtypes and IFNβ Influence Chronic Mucosal HIV-1 Pathogenesis 

Lee CG, Kim T, Hong S, et al | Front Pharmacol | 2021

Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing

Kharlamova N, Hermanrud C, Dunn N, et al | Front Immunol | 2020

Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier 

Lallemand C, Ferrando-Miguel R, Auer M, et al | Front Immunol | 2020

Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma 

Sjögren J, Lood R, Nägeli A. | Glycobiology | 2020

On enzymatic remodeling of IgG glycosylation; unique tools with broad applications 

Meier S, Bohnacker S, Klose CJ, et al | Nat Commun | 2019

The molecular basis of chaperone-mediated interleukin 23 assembly control 

Mojtahed Poor S, Ulshöfer T, Gabriel LA, et al | Clin Exp Immunol | 2019

Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab 

Hyun JW, Kim G, Kim Y, et al | J Clin Neurol | 2018

Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis 

Lallemand C, Liang F, Staub F, et al | J Immunol Res | 2017

A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies 

Link J, Ramanujam R, Auer M, et al | PLoS One | 2017

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results 

Bachelet D, Hässler S, Mbogning C, et al | PLoS One | 2016

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis 

Hermanrud C, Ryner M, Luft T, Jensen PE, et al | J Immunol Methods | 2016

Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta

Jacobson JM, Bosinger SE, Kang M, et al | AIDS Res Hum Retroviruses | 2016

The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1 AIDS Res Hum Retroviruses

Pogue SL, Taura T, Bi M, et al | PLoS One | 2016

Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity 

van Bezooijen JS, Koch BC, et al | Ther Drug Monit | 2016

Comparison of Three Assays to Quantify Infliximab, Adalimumab, and Etanercept Serum Concentrations

Aalbers CJ, Bevaart L, Loiler S, et al | PLoS One | 2015

Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis 

Eng GP, Bendtzen K, Bliddal H, et al | Arthritis | 2015

Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study 

Hermanrud C, Ryner ML, et al |  J Interferon Cytokine Res | 2014

Anti-interferon beta antibody titers strongly correlate between two bioassays and in vivo biomarker expression, and indicates that a titer of 150 TRU/mL is a biologically functional cut-point

Mora J, Given Chunyk A, et al | AAPS J | 2014

Next generation ligand binding assays-review of emerging technologies' capabilities to enhance throughput and multiplexing

Cardillo TM, Trisal P, et al | BMC Cancer | 2013

Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro 

Hardy GA, Sieg S, Rodriguez B, et al | PLoS One | 2013

Interferon-α is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers

Wadhwa M, Subramanyam M, Goelz S, et al |  J Interferon Cytokine Res | 2013

Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β

Tattermusch S, Skinner JA, Chaussabel D, et al | PLoS Pathog | 2012

Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy

Rossi EA, Rossi DL, Cardillo TM, et al | Blood | 2011

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers 

Rossi EA, Goldenberg DM, et al | Blood | 2009

CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas